IP Library Granted Patent US 7,122,569
Granted Patent B2
US 7,122,569 · App. 10/825,270 · Granted Oct 17, 2006

Ethylene glycol esters as photoactive agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,122,569
App. No.
10/825,270
Granted
Oct 17, 2006
Kind
B2
Abstract

New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R 1 is independently alkyl (1–6C); each n is independently an integer of 0–6; and R 2 is vinyl or a derivative form thereof.

Claims (32)

1. A method for modulating the activity of a kinase involved in signal transduction in a subject in need thereof comprising irradiating said subject with light after administration of a compound of the formula

or their 1,4-diene isomers

or the metallated and/or labeled and/or conjugated forms thereof

wherein each R 1 is independently alkyl (1–6C);

each n is independently an integer of 0–6; and

R 2 is vinyl or a derivative thereof,

thereby modulating the activity of said kinase involved in signal transduction.

2. The method of claim 1 wherein in said compound, R 2 is vinyl, —CHOR′, —CHO, —COOR′, —CH(OR′)CH 3 , —CH(OR′)CH 2 OR′, —CH(SR′)CH 3 , —CH(NR′) 2 CH 3 , —CH(CN)CH 3 , —CH(COOR′)CH 3 , —CH(OOCR′)CH 3 , —CH(NR′COR′)CH 3 , —CH(CONR′ 2 )CH 3 , —CH(halo)CH 3 , or —CH(halo)CH 2 (halo) wherein R′ is H, or a hydrocarbon radical (1–6C) optionally substituted with a heteroatom substituent.

3. The method of claim 1 wherein in said compound, R 2 is an organic group of less than 12C resulting from derivatization of a vinyl substituent.

4. The method of claim 1 wherein in said compound, R 2 is a group containing 1–3 tetrapyrrole nuclei.

5. The method of claim 1 wherein said compound is in a metallated form.

6. The method of claim 1 wherein said compound is in conjugated form.

7. The method of claim 1 wherein said compound is labeled.

8. The method of claim 1 wherein said compound does not contain a metal ion.

9. The method of claim 1 wherein in said compound, R 2 is vinyl.

10. The method of claim 1 wherein in said compound, each R 1 is methyl.

11. The method of claim 1 wherein in said compound, both n are 2.

12. The method of claim 11 wherein in said compound, R 2 is vinyl and both R 1 are methyl.

13. The method of claim 1 wherein said compound is selected from formulae 1–4.

14. The method of claim 13 wherein in said compound, R 2 is vinyl, —CHOR′, —CHO, —COOR′, —CH(OR′)CH 3 , —CH(OR′)CH 2 OR′, —CH(SR′)CH 3 , —CH(NR′) 2 CH 3 , —CH(CN)CH 3 , —CH(COOR′)CH 3 , —CH(OOCR′)CH 3 , —CH(NR′COR′)CH 3 , —CH(CONR′ 2 )CH 3 , —CH(halo)CH 3 , or —CH(halo)CH 2 (halo) wherein R′ is H, or a hydrocarbon radical (1–6C) optionally substituted with a heteroatom substituent.

15. The method of claim 13 wherein in said compound, R 2 is an organic group of less than 12C resulting from derivatization of a vinyl substituent.

16. The method of claim 13 wherein in said compound, R 2 is vinyl.

17. The method of claim 13 wherein in said compound, each R 1 is methyl.

18. The method of claim 13 wherein in said compound, both n are 2.

19. The method of claim 18 wherein in said compound, R 2 is vinyl and both R 1 methyl.

20. The method of claim 12 wherein said compound is A-EA6 or B-EA6 or the metallated and/or labeled and/or conjugated forms thereof.

21. The method of claim 20 wherein said compound is in a metallated form.

22. The method of claim 20 wherein said compound is in conjugated form.

23. The method of claim 20 wherein said compound is labeled.

24. The method of claim 20 wherein said compound does not contain a metal ion.

25. The method of claim 1 wherein said kinase is a mitogenic pathway kinase or a stress pathway kinase.

26. The method of claim 25 , wherein said kinase is p70 S6K, c-jun or HSP27.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Jul 19, 2017
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043045/0959 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ADDRESS CHANGE Recorded May 15, 2014
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Reel/Frame 032897/0450 →
PATENT ASSIGNMENT AGREEMENT Recorded Dec 9, 2013
From: QLT INC.; QLT OPHTHALMICS, INC.
To: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Reel/Frame 031784/0833 →